Literature DB >> 21493957

Multiple congenital anomalies-hypotonia-seizures syndrome is caused by a mutation in PIGN.

Gal Maydan1, Iris Noyman, Adi Har-Zahav, Ziva Ben Neriah, Metsada Pasmanik-Chor, Adva Yeheskel, Adi Albin-Kaplanski, Idit Maya, Nurit Magal, Efrat Birk, Amos J Simon, Ayelet Halevy, Gideon Rechavi, Mordechai Shohat, Rachel Straussberg, Lina Basel-Vanagaite.   

Abstract

BACKGROUND: This study reports on a hitherto undescribed autosomal recessive syndrome characterised by dysmorphic features and multiple congenital anomalies together with severe neurological impairment, chorea and seizures leading to early death, and the identification of a gene involved in the pathogenesis of the disease.
METHODS: Homozygosity mapping was performed using Affymetrix Human Mapping 250k NspI arrays. Sequencing of all coding exons of the candidate genes was performed with primer sets designed using the Primer3 program. Fluorescence activated cell sorting was performed using conjugated antibody to CD59. Staining, acquisition and analysis were performed on a FACSCalibur flow cytometer.
RESULTS: Using homozygosity mapping, the study mapped the disease locus to 18q21.32-18q22.1 and identified the disease-causing mutation, c.2126G→A (p.Arg709Gln), in PIGN, which encodes glycosylphosphatidylinositol (GPI) ethanolamine phosphate transferase 1, a protein involved in GPI-anchor biosynthesis. Arginine at the position 709 is a highly evolutionarily conserved residue located in the PigN domain. The expression of GPI linked protein CD59 on fibroblasts from patients as compared to that in a control individual showed a 10-fold reduction in expression, confirming the pathogenic consequences of the mutation on GPI dependent protein expression.
CONCLUSIONS: The abundant expression of PIGN in various tissues is compatible with the diverse phenotypic features observed in the patients and with the involvement of multiple body systems. The presence of developmental delay, hypotonia, and epilepsy combined with multiple congenital anomalies, especially anorectal anomalies, should lead a clinician to suspect a GPI deficiency related disorder.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21493957     DOI: 10.1136/jmg.2010.087114

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  64 in total

1.  Neurology of inherited glycosylation disorders.

Authors:  Hudson H Freeze; Erik A Eklund; Bobby G Ng; Marc C Patterson
Journal:  Lancet Neurol       Date:  2012-05       Impact factor: 44.182

2.  The phenotype of a germline mutation in PIGA: the gene somatically mutated in paroxysmal nocturnal hemoglobinuria.

Authors:  Jennifer J Johnston; Andrea L Gropman; Julie C Sapp; Jamie K Teer; Jodie M Martin; Cyndi F Liu; Xuan Yuan; Zhaohui Ye; Linzhao Cheng; Robert A Brodsky; Leslie G Biesecker
Journal:  Am J Hum Genet       Date:  2012-02-02       Impact factor: 11.025

Review 3.  Neurological aspects of human glycosylation disorders.

Authors:  Hudson H Freeze; Erik A Eklund; Bobby G Ng; Marc C Patterson
Journal:  Annu Rev Neurosci       Date:  2015-04-02       Impact factor: 12.449

Review 4.  Congenital disorders of glycosylation.

Authors:  Irene J Chang; Miao He; Christina T Lam
Journal:  Ann Transl Med       Date:  2018-12

5.  Both PIGA and PIGL mutations cause GPI-a deficient isolates in the Tk6 cell line.

Authors:  Janice A Nicklas; Elizabeth W Carter; Richard J Albertini
Journal:  Environ Mol Mutagen       Date:  2015-05-13       Impact factor: 3.216

Review 6.  Cardiac complications of congenital disorders of glycosylation (CDG): a systematic review of the literature.

Authors:  D Marques-da-Silva; R Francisco; D Webster; V Dos Reis Ferreira; J Jaeken; T Pulinilkunnil
Journal:  J Inherit Metab Dis       Date:  2017-07-19       Impact factor: 4.982

7.  Application of custom-designed oligonucleotide array CGH in 145 patients with autistic spectrum disorders.

Authors:  Barbara Wiśniowiecka-Kowalnik; Monika Kastory-Bronowska; Magdalena Bartnik; Katarzyna Derwińska; Wanda Dymczak-Domini; Dorota Szumbarska; Ewa Ziemka; Krzysztof Szczałuba; Maciej Sykulski; Tomasz Gambin; Anna Gambin; Chad A Shaw; Tadeusz Mazurczak; Ewa Obersztyn; Ewa Bocian; Paweł Stankiewicz
Journal:  Eur J Hum Genet       Date:  2012-10-03       Impact factor: 4.246

Review 8.  Understanding human glycosylation disorders: biochemistry leads the charge.

Authors:  Hudson H Freeze
Journal:  J Biol Chem       Date:  2013-01-17       Impact factor: 5.157

9.  Mutations in PGAP3 impair GPI-anchor maturation, causing a subtype of hyperphosphatasia with mental retardation.

Authors:  Malcolm F Howard; Yoshiko Murakami; Alistair T Pagnamenta; Cornelia Daumer-Haas; Björn Fischer; Jochen Hecht; David A Keays; Samantha J L Knight; Uwe Kölsch; Ulrike Krüger; Steffen Leiz; Yusuke Maeda; Daphne Mitchell; Stefan Mundlos; John A Phillips; Peter N Robinson; Usha Kini; Jenny C Taylor; Denise Horn; Taroh Kinoshita; Peter M Krawitz
Journal:  Am J Hum Genet       Date:  2014-01-16       Impact factor: 11.025

10.  A homozygous PIGO mutation associated with severe infantile epileptic encephalopathy and corpus callosum hypoplasia, but normal alkaline phosphatase levels.

Authors:  Yoav Zehavi; Anja von Renesse; Etty Daniel-Spiegel; Yonatan Sapir; Luci Zalman; Ilana Chervinsky; Markus Schuelke; Rachel Straussberg; Ronen Spiegel
Journal:  Metab Brain Dis       Date:  2017-09-13       Impact factor: 3.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.